NCT00985933

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

A Single Center, Double-Blind, Randomized, Double Dummy, Placebo-Controlled, Three-Period Crossover Study to Assess the Effects of a mGluR2/3 Positive Allosteric Modulator [AZD8529] Upon Ketamine-Induced Cortical Stimulation and Impairment of Working-Memory Related Activation of the Prefrontal Cortex

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 21 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Conditions

• Healthy
• Memory Impairment

Interventions

Type	Name	Description
DRUG	AZD8529	6 capsules by mouth 1 time 12 to 24 prior to assessments
DRUG	Placebo to match AZD8529	6 capsules by mouth 1 time 12 to 24 hours prior to assessments

Timeline

• Start date: 2010-02-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2009-09-29
• Last updated: 2011-05-04

Locations

1 site across 1 country: United States